ArticleBioPsychoSocial medicine2024
Disabling symptoms associated with increased axillary temperature in patients with functional hyperthermia.
Article in BioPsychoSocial medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundI previously reported a case of functional hyperthermia (FH) in a patient with an axillary temperature just slightly above 37.0 °C who persistently requested treatment. Because the severity of her fatigue increased remarkably when her axillary temperature increased above 37.0 °C, she felt that the temperature of 37.0 °C was disabling. In the present study, I analyzed a larger number of patients with FH to investigate the incidence of disabling symptoms with increasing body temperature, the kinds of symptoms associated with increased body temperature, and the temperatures at which these symptoms became disabling. MAIN BODY: Twenty patients with FH (7 men, 13 women; mean age ± standard deviation, 31.2 ± 10.9 years) who visited my department were asked whether they had any disabling symptoms associated with an increase in axillary temperature and, if so, at what temperature the symptoms became disabling. Sixteen of 20 patients (80.0%) responded that they had such symptoms, which included worsening of general fatigue (n = 12, 75.0%), feelings that their brain did not work properly (n = 5, 31.3%), inability to move (n = 4, 25.0%), hot flashes/feeling of heat (n = 3, 18.8%), headache (n = 2, 12.5%), dizziness (n = 2, 12.5%) and anorexia (n = 1, 6.3%). The axillary temperatures at which patients felt worsening fatigue ranged from 37.0 °C to 37.4 °C in 7 of the 12 patients (58.3%) who experienced worsening fatigue. The patients also reported that the disabling symptoms, with the exception of headache, were not alleviated by antipyretics.
conclusionsMany patients with FH reported worsening fatigue as a disabling symptom associated with increased axillary temperature; more than half of those patients experienced worsening fatigue in the temperature range of 37.0 °C to 37.4 °C. These findings suggest that the reasons patients with FH consider 37 °C disabling and seek medical treatment are that physical symptoms such as fatigue worsen at 37 °C, although this temperature is assumed by many physicians to be within the normal range or just above the normal range of axillary temperature, and that most hyperthermia-associated symptoms are not alleviated by antipyretic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.